Hostname: page-component-7b7567c8c-jvr6b Total loading time: 0 Render date: 2026-11-15T23:30:49.691Z Has data issue: false hasContentIssue false

Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

Published online by Cambridge University Press:  29 April 2022

Hongkai Bao*
Affiliation:
Department of Pharmacy, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Yi Guo
Affiliation:
Department of Pharmacy, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Mei H. Chang
Affiliation:
Department of Pharmacy, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Terrence McSweeney
Affiliation:
Department of Pharmacy, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Austin M. Golia
Affiliation:
Department of Pharmacy, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Kelsie Cowman
Affiliation:
Network Performance Group, Montefiore Health System, Bronx, New YorkDivision of Infectious Diseases, Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Rachel Bartash
Affiliation:
Division of Infectious Diseases, Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Brenda I. Anosike
Affiliation:
Division of Infectious Diseases, Children’s Hospital at Montefiore, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
Priya Nori
Affiliation:
Division of Infectious Diseases, Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York
*
Author for correspondence: Hongkai Bao, Department of Pharmacy, Montefiore Health System, Wakefield Division, 600 E 233rd Street G-55, Bronx, NY 10466. E-mail: hbao@montefiore.org

Abstract

Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.

Information

Type
Review
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Outpatient COVID-19 Therapeutics Currently Recommended by National Guidelines23,29

Figure 1

Fig. 1.Recommendations by antimicrobial stewardship programs to overcome barriers to outpatient COVID-19 antiviral prescribing.